Preview

Современная ревматология

Расширенный поиск

Хроническая болезнь почек: роль гиперурикемии и возможности урат-снижающей терапии

https://doi.org/10.14412/1996-7012-2018-1-60-65

Полный текст:

Аннотация

Результаты многочисленных эпидемиологических исследований позволяют предполагать взаимосвязь хронической болезни почек (ХБП) и асимптоматической гиперурикемии, при  этом появляется все больше свидетельств того, что повышенный уровень мочевой кислоты  (МК) является причиной повреждения почек. Среди возможных механизмов развития ХБП  при гиперурикемии называют иммунное воспаление, как опосредованное кристаллизацией  МК, так и не зависящее от кристаллообразования, влияние на активность ренин- ангиотензин-альдостероновой системы. Имеющиеся в настоящий момент оптимистичные  данные об эффективности медикаментозной коррекции гиперурикемии на разных стадиях  ХБП, обоснованы прежде всего длительным приемом ингибиторов ксантиноксидазы  (аллопуринол, фебуксостат) и позволяют рассматривать урат-снижающую терапию как  потенциально  нефропротективную. В то же время для их подтверждения необходимы дальнейшие крупные  рандомизированные контролируемые исследования.

Об авторе

М. С. Елисеев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А


Литература

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Sep;84(3):1-150.

2. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011 Dec;80(12):1258-70. doi: 10.1038/ki.2011.368. Epub 2011 Oct 12.

3. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007 Aug;72(3):247-59. Epub 2007 Jun 13.

4. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18.

5. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980- 2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1459-1544. doi: 10.1016/S0140-6736(16)31012-1.

6. Johnson RJ, Nakagawa T, Jalal D, et al. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013 Sep;28(9):2221-8. doi: 10.1093/ndt/gft029. Epub 2013 Mar 29.

7. Kang DH, Chen W. Uric acid and chronic kidney disease: new understanding of an old problem. Semin Nephrol. 2011 Sep;31(5):447-52. doi: 10.1016/j.semnephrol.2011.08.009.

8. Kratzer JT, Lanaspa MA, Murphy MN, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A. 2014 Mar 11;111(10): 3763-8. doi: 10.1073/pnas.1320393111. Epub 2014 Feb 18.

9. Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of uratelowering therapy. Rheumatology (Oxford). 2018 Jan 1; 57(suppl_1):i47-i50. doi: 10.1093/rheumatology/kex432.

10. Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep. 2013 Jun; 15(3):175-81. doi: 10.1007/s11906-013-0344-5.

11. Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol. 2017 Dec;36(12): 2637-2644. doi: 10.1007/s10067-017-3851-y. Epub 2017 Oct 4.

12. Желябина ОВ, Елисеев МС. Диета при подагре и гиперурикемии. Научно-практическая ревматология. 2017; 55(4):436-45. [Zhelyabina OV, Eliseev MS. Diet in gout and hyperuricemia. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017; 55(4):436-45. (In Russ.)]. doi: 10.14412/1995-4484-2017-436-445

13. Bjornstad P, Lanaspa MA, Ishimoto T, et al. Fructose and uric acid in diabetic nephropathy. Diabetologia. 2015 Sep;58(9): 1993-2002. doi: 10.1007/s00125-015-3650-4. Epub 2015 Jun 7.

14. Елисеев МС, Барскова ВГ, Якунина ИА. Диагноз подагра – противопоказание для назначения диуретиков. Фарматека. 2003;(5):67-70. [Eliseev MS, Barskova VG, Yakunina IA. Gout is a contraindication for diuretics. Farmateka. 2003;(5):67-70. (In Russ.)].

15. Ryckman C, Gilbert C, de Medicis R, et al. Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils. J Leukoc Biol. 2004 Aug;76(2):433-40. Epub 2004 Apr 23.

16. Li S, Sanna S, Maschio A, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet. 2007 Nov;3(11):e194.

17. Reginato AM, Mount DB, Yang I, et al. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2012 Oct;8(10):610-21. doi: 10.1038/nrrheum.2012.144. Epub 2012 Sep 4.

18. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012 Nov;19(6): 358-71. doi: 10.1053/j.ackd.2012.07.009.

19. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016 Oct 22;388(10055): 2039-2052. doi: 10.1016/S0140-6736(16)00346-9. Epub 2016 Apr 21.

20. Finn WF. Kidney Disease and Gout: The Role of the Innate Immune System. The Open Urology & Nephrology Journal. 2016; 9(Suppl 1:M3):12.

21. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001 Nov;38(5):1101-6.

22. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002 Dec;13(12): 2888-97.

23. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressureindependent mechanism. Am J Physiol Renal Physiol. 2002 Jun;282(6):F991-7.

24. Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002 Nov; 283(5):F1105-10.

25. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005 Jan;67(1):237-47.

26. Kohagura K, Kochi M, Miyagi T, et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res. 2013 Jan;36(1):43-9. doi: 10.1038/hr.2012.135. Epub 2012 Sep 6.

27. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol. 2005 Mar;16(3):791-9. Epub 2005 Jan 26.

28. Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007 Aug;50(2):239-47.

29. Weiner DE, Tighiouart H, Elsayed EF, et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008 Jun;19(6):1204-11. doi: 10.1681/ASN.2007101075. Epub 2008 Mar 12.

30. Bellomo G, Venanzi S, Verdura C, et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis. 2010 Aug;56(2):264-72. doi: 10.1053/j.ajkd.2010.01.019. Epub 2010 Apr 10.

31. Sonoda H, Takase H, Dohi Y, Kimura G. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol. 2011;33(4):352-7. doi: 10.1159/000326848. Epub 2011 Mar 25.

32. Barkas F, Elisaf M, Liberopoulos E, et al. Uric acid and incident chronic kidney disease in dyslipidemic individuals. Curr Med Res Opin. 2017 Sep 21:1-7. doi: 10.1080/03007995.2017.1372157. [Epub ahead of print]

33. Bakan A, Oral A, Elcioglu OC, et al. Hyperuricemia is associated with progression of IgA nephropathy. Int Urol Nephrol. 2015 Apr;47(4):673-8. doi: 10.1007/s11255-015-0939-7. Epub 2015 Mar 12.

34. Caliskan Y, Ozluk Y, Celik D, et al. The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy. Kidney Blood Press Res. 2016;41(2):148- 57. doi: 10.1159/000443415. Epub 2016 Feb 26.

35. Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-Normal Serum Uric Acid Increases Risk of Early Progressive Renal Function Loss in Type 1 Diabetes. Diabetes Care. 2010 Jun;33(6):1337-43. doi: 10.2337/dc10-0227. Epub 2010 Mar 23.

36. Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for newonset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014 Jul 27;15:122. doi: 10.1186/1471-2369-15-122.

37. Xu X, Hu J, Song N, et al. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol. 2017 Jan 17;18(1):27. doi: 10.1186/s12882-016-0433-1.

38. Richette P, Bardin T. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017 Jul 3;15(1):123. doi: 10.1186/s12916-017-0890-9.

39. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and metaanalysis. BMC Nephrol. 2015 Apr 19;16:58. doi: 10.1186/s12882-015-0047-z.

40. Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and metaanalysis. Nephrol Dial Transplant. 2014 Feb;29(2):406-13. doi: 10.1093/ndt/gft378. Epub 2013 Sep 15.

41. Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: longterm follow-up of a randomized clinical trial. Am J Kidney Dis. 2015 Apr;65(4):543-9. doi: 10.1053/j.ajkd.2014.11.016. Epub 2015 Jan 13.

42. Su X, Xu B, Yan B, et al. Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis. PLoS One. 2017 Nov 2;12(11):e0187550. doi: 10.1371/journal.pone.0187550. eCollection 2017.

43. Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: longterm follow-up of a randomized clinical trial. Am J Kidney Dis. 2015 Apr;65(4):543-9. doi: 10.1053/j.ajkd.2014.11.016. Epub 2015 Jan 13.

44. Zhao L, Takano Y, Horiuchi H. Effect of febuxostat, a novel non-purine, selective inhibitor of xantine oxidase (NP-SIXO), on enzymes in purine and pyrimidine methabolism pathway. Arthritis Rheum. 2003; 48 (Suppl. 9):S531.

45. Swan S, Khosravan R, Mauer MD, et al. Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a novel non-purine, selective inhibitor of xanthine oxidase. Arthritis Rheum 2003; 48(Suppl. 9):529.

46. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011 Sep;38(9):1957-9. doi: 10.3899/jrheum.110092. Epub 2011 Jul 1.

47. Richette P, Doherty M, Pascual E. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25.

48. Van Echteld IA, van Durme C, Falzon L, et al. Treatment of Gout Patients with Impairment of Renal Function: A Systematic Literature Review. J Rheumatol Suppl. 2014 Sep;92:48-54. doi: 10.3899/jrheum.140462.

49. Tanaka K, Nakayama M, Kanno M, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol. 2015 Dec; 19(6):1044-53. doi: 10.1007/s10157-015-1095-1. Epub 2015 Feb 13.

50. Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, doubleblind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015 Dec;66(6):945-50. doi: 10.1053/j.ajkd.2015.05.017. Epub 2015 Jul 30.

51. Baek CH, Kim H, Yang WS, et al. Efficacy and Safety of Febuxostat in Kidney Transplant Patients. Exp Clin Transplant. 2017 Dec 18. doi: 10.6002/ect.2016.0367. [Epub ahead of print]

52. Chou HW, Chiu HT, Tsai CW, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2017 Nov 17. doi: 10.1093/ndt/gfx313. [Epub ahead of print].

53. Juge PA, Truchetet ME, Pillebout E, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2017 Oct;84(5):595-598. doi: 10.1016/j.jbspin.2016.09.020. Epub 2016 Nov 4.


Для цитирования:


Елисеев М.С. Хроническая болезнь почек: роль гиперурикемии и возможности урат-снижающей терапии. Современная ревматология. 2018;12(1):60-65. https://doi.org/10.14412/1996-7012-2018-1-60-65

For citation:


Eliseev M.S. Chronic kidney disease: the role of hyperuricemia and the possibility of urate-lowering therapy. Modern Rheumatology Journal. 2018;12(1):60-65. (In Russ.) https://doi.org/10.14412/1996-7012-2018-1-60-65

Просмотров: 327


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)